Author | Daniel S. Raccuia, PharmD candidate 2016

Articles

FDA approves rolapitant to prevent chemotherapy-induced nausea and vomiting

June 10, 2016

Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.